NCT07386912Not yet recruiting
Investigation of the Effects of Oxidized Antigens on the T-Cell Response and the Epigenetic Reprogramming of Neutrophils in Lung Diseases - OXIGENE -
Source: ClinicalTrials.gov · Last updated 4 Feb 2026
Brief summary (registry, in English)
The OXIGENE study is a research project that aims to better understand how the immune system behaves in people with lung diseases such as asthma, COPD, pneumonia, tuberculosis, and viral lung infections. By analyzing a single blood sample, the study examines how certain immune cells react during inflammation and infection, and whether lasting changes in these cells influence how strongly the body responds to disease. Although participants do not receive direct medical benefit, the results may help improve future diagnosis and treatment of lung diseases by providing deeper insight into immune responses.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 27 Jan 2026
- Start date
- 1 Feb 2026
- Primary completion date
- Dec 2028
- Lead sponsor
- Research Center Borstel
- Diseases
- Tuberculosis, Asthma, COPD
- NCT number
- NCT07386912
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Feb 2026 to the primary completion date, Dec 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Immunosuppressive therapy or known severe immunodeficiency that could interfere with the interpretation of cellular immune responses.
Other illness
- Active malignant disease or ongoing cancer therapy (e.g., chemotherapy or immunotherapy), due to potential immunological confounding.
- Acute unstable clinical condition that, in the opinion of the treating physician, makes study participation unreasonable.
- Known intolerance to blood sampling or relevant hematological disorders that could compromise the safety or feasibility of venipuncture.
Other
- Pregnancy or breastfeeding, for general research-ethical reasons and to protect vulnerable populations.
- Lack of capacity to provide informed consent or insufficient understanding of the study content despite supportive explanation.
Who the study is looking for
- Diagnosis of an acute or chronic inflammatory lung disease, infectious or non-infectious, including asthma, COPD, pneumonia, tuberculosis, or viral pulmonary infection (e.g., COVID-19, influenza).
- Age ≥ 18 years at the time of informed consent.
- Ability to provide informed consent and consent to the collection and processing of clinical and laboratory data, as well as to the analysis of blood samples as part of study participation.
- Sufficient physical condition to undergo a single venous blood draw (approximately 50 mL), as assessed by the treating physician.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical Service Center MVZ, Research Center Borstel, Leibniz Lung Center Coordinator of this site? Confirm its status | Borstel | Germany | Unknown status |
| Department of Pulmonology, University Hospital Schleswig-Holstein Coordinator of this site? Confirm its status | Kiel | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.